Market cap
$1,634 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -48.86 | -135.62 | -202.86 |
| Net Profit | -5.40 | -107.41 | -107.14 | -218.75 | -218.47 |
| EPS | 20.97 | -2.40 | 42.41 | 22.56 | 13.83 |
| Book Value | -- | -- | -58.40 | -58.04 | -50.50 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -96.01 | -73.14 | -71.85 | -122.28 | -80.82 |
| Return on Capital
| -96.01 | -73.14 | -- | -122.28 | -80.82 |
| Return on Assets
| -81.48 | -63.69 | -51.28 | -96.13 | -70.57 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
-122.28
|
-80.82
|
-84.92
|
-34.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-71.85
Lower than Peers by 31.52
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
-71.85
|
-122.28
|
-80.82
|
-84.92
|
-34.50
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-51.28
Lower than Peers by 20.03
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
-51.28
|
-96.13
|
-70.57
|
-77.74
|
-32.50
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-48.86
Lower than Peers by 47.85
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
-48.86
|
-92.62
|
-12.71
|
-126.51
|
35.99
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-107.14
Lower than Peers by 99.61
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
-107.14
|
-95.54
|
-12.71
|
-127.07
|
36.14
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
42.41
Higher than Peers by 28.18
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
42.41
|
0.30
|
-5.41
|
0.95
|
0.55
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-7.98
Higher than Peers by 2.15
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
-7.98
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
10.01
Higher than Peers by 4.20
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
10.01
|
3.88
|
6.76
|
10.45
|
13.06
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
10.01
Higher than Peers by 4.31
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
10.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
-817.41
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
42,426.07
|
29,515.01
|
52,291.63
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
-7.02
|
-4.09
|
-0.95
|
-0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
8.89
Higher than Peers by 3.57
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
8.89
|
7.99
|
2.77
|
0.85
|
0.02
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
1.87
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
1.87
|
-6.01
|
-2.45
|
0.23
|
2.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
1,634
Higher than Peers by 1,493
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Forte Biosciences (FBRX)
|
1,634
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|